Safety, Tolerability, PK and PD of BMS-986141 in Healthy Subjects

Phase 1, randomised, double-blind trial of bms-986141 in thrombosis (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety measured by number and percent of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory… and Tolerability measured by number and percent of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs,… Started Sep 2014; status: completed.